ASPHF (Ascentage Pharma Group International) Forward PE Ratio: 74.26 (As of Jul. 06, 2026)


ASPHF Ascentage Pharma Group International ASPHF
66 GF Score
Price $4.53
GF Value $7.38
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is Ascentage Pharma Group International Forward PE Ratio?

Ascentage Pharma Group International ASPHF -3.51% 66 Forward PE Ratio is 74.26 as of Jul. 06, 2026. GuruFocus rates ASPHF with a GF Score™ of 66/100 and a GF Value™ of $7.38 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 354 Biotechnology companies, Ascentage Pharma Group International ranks worse than 82.49% on this metric.

Ascentage Pharma Group International's Forward PE Ratio for today is 74.26.

Ascentage Pharma Group International's PE Ratio without NRI for today is 0.00.

Ascentage Pharma Group International's PE Ratio (TTM) for today is 0.00.


Ascentage Pharma Group International  (OTCPK:ASPHF) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .


Ascentage Pharma Group International Forward PE Ratio Related Terms


Ascentage Pharma Group International Forward PE Ratio Historical Data

* Premium members only.

The historical data trend for Ascentage Pharma Group International's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ascentage Pharma Group International Forward PE Ratio Chart

Ascentage Pharma Group International Annual Data
Trend 2025-12
Forward PE Ratio
25.62

Ascentage Pharma Group International Semi-Annual Data
2025-12
Forward PE Ratio 25.62

ASPHF vs VRTX, REGN, ALNY: Forward PE Ratio Comparison

For the Biotechnology subindustry, Ascentage Pharma Group International's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ascentage Pharma Group International Forward PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ascentage Pharma Group International's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where Ascentage Pharma Group International's Forward PE Ratio falls into.


ASPHF
66GF Score
Ascentage Pharma Group International ASPHF
Forward PE Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ascentage Pharma Group International Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.

Frequently Asked Questions Learn more about Forward PE Ratio →
What does a Forward PE Ratio of 74.26 mean?
Ascentage Pharma Group International (ASPHF) has a Forward PE Ratio of 74.26 as of Jul. 06, 2026. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Ascentage Pharma Group International and its competitors. According to the industry distribution chart, Ascentage Pharma Group International ranks #292 out of 354 companies in the Biotechnology industry, placing it in the top 82.5%.
Is Ascentage Pharma Group International's Forward PE Ratio too high?
Ascentage Pharma Group International's current Forward PE Ratio is 74.26. The Biotechnology industry median Forward PE Ratio is 22.33. Ascentage Pharma Group International's value of 74.26 is 232.6% above this industry median. Based on the distribution chart, Ascentage Pharma Group International ranks #292 out of 354 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Ascentage Pharma Group International has a GF Score™ of 66/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Ascentage Pharma Group International's Forward PE Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Ascentage Pharma Group International ranks #292 out of 354 companies for Forward PE Ratio. This places Ascentage Pharma Group International in the lower half of its industry. The industry median Forward PE Ratio is 22.33. Ascentage Pharma Group International's value of 74.26 is 232.6% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward PE Ratio for a Biotechnology company?
The median Forward PE Ratio among Biotechnology companies is 22.33, based on 354 companies in the industry. Companies in the top quartile (top 25%) have a Forward PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Forward PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ascentage Pharma Group International's current Forward PE Ratio of 74.26 is 232.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward PE Ratio mean?
A high Forward PE Ratio can signal that a stock is expensive relative to its fundamentals. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Ascentage Pharma Group International and its competitors. For the Biotechnology industry, the median Forward PE Ratio is 22.33 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ascentage Pharma Group International's current Forward PE Ratio is 74.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ascentage Pharma Group International stock overvalued right now?
Based on GuruFocus' analysis, Ascentage Pharma Group International (ASPHF) is currently considered Possible Value Trap. The stock's GF Value™ is $7.38, compared to a current price of $4.53 — trading 38.6% below its estimated fair value. The current Forward PE Ratio is 74.26 and 232.6% above the Biotechnology industry median of 22.33. Ascentage Pharma Group International's overall GF Score™ is 66/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward PE Ratio calculated?
Forward PE Ratio is calculated from a company's financial statements. For Ascentage Pharma Group International (ASPHF), the current Forward PE Ratio is 74.26 as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ascentage Pharma Group International (ASPHF) Overvalued in 2026?

Based on GuruFocus' analysis, Ascentage Pharma Group International stock appears to be undervalued. The current stock price of $4.53 is trading 38.6% below its estimated GF Value™ of $7.38. GuruFocus considers Ascentage Pharma Group International to be Possible Value Trap.

Key valuation signals for ASPHF:

  • Forward PE Ratio: 74.26
  • GF Value™: $7.38 vs. price of $4.53 (38.6% below fair value)
  • GF Score™: 66/100 with 7 warning signs
  • Industry Position: 232.6% above the Biotechnology median (#292 of 354)

No single metric tells the full story. See the ASPHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Ascentage Pharma Group International Business Description

Address 68 Xinqing Road, Suzhou Industrial Park, Jiangsu, Suzhou, CHN, 215000
Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The Group has one reportable operating segment, which is discovering, developing, and commercializing therapies to address medical needs in hematological malignancies and currently has seven drug candidates in pipeline under research. The company's geographical segments include the United States and Mainland China.
66GF Score

Get the complete analysis for ASPHF

Forward PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.53
Price
$7.38
GF Value